🇺🇸 FDA

Drug profile · INN

relacorilant

LIFYORLI (COPACKAGED)

approved
US status
approved
Patents linked
8
News articles
0

Quick answer

relacorilant (LIFYORLI (COPACKAGED)) is an FDA-listed pharmaceutical active ingredient. Associated with CORCEPT THERAPEUTICS INC. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN relacorilant
Brand LIFYORLI (COPACKAGED)
Route ORAL
Formulation CAPSULE
Originator CORCEPT THERAPEUTICS INC

Related patents

Search patents →

  1. US 12097192

    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11944617

    Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4

    Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11925626

    Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

    Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11684612

    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

    Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11590113

    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

    Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11464764

    Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound

    Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11285145

    Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11058670

    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator

    Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is relacorilant?

relacorilant (LIFYORLI (COPACKAGED)) is an FDA-listed pharmaceutical active ingredient. Associated with CORCEPT THERAPEUTICS INC. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for relacorilant?

LIFYORLI (COPACKAGED) is a marketed brand name for relacorilant. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of relacorilant?

relacorilant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.